<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="pcmr70055" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pigment Cell Melanoma Res</journal-id><journal-id journal-id-type="iso-abbrev">Pigment Cell Melanoma Res</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">PCMR</journal-id><journal-title-group><journal-title>Pigment Cell &amp; Melanoma Research</journal-title></journal-title-group><issn pub-type="ppub">1755-1471</issn><issn pub-type="epub">1755-148X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474564</article-id><article-id pub-id-type="pmcid-ver">PMC12474564.1</article-id><article-id pub-id-type="pmcaid">12474564</article-id><article-id pub-id-type="pmcaiid">12474564</article-id><article-id pub-id-type="pmid">41006694</article-id><article-id pub-id-type="doi">10.1111/pcmr.70055</article-id><article-id pub-id-type="publisher-id">PCMR70055</article-id><article-id pub-id-type="other">25-SC-077</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Short Communication</subject></subj-group><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Germline <styled-content style="fixed-case" toggle="no">
<italic toggle="no">CDKN2A</italic>
</styled-content> Variant Cascade Testing Across Four Generations Reveals Familial Melanoma&#8211;Breast Cancer Genotype&#8211;Phenotype Correlation</article-title></title-group><contrib-group><contrib id="pcmr70055-cr-0001" contrib-type="author"><name name-style="western"><surname>Berkman</surname><given-names initials="J">Jennifer</given-names></name><xref rid="pcmr70055-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcmr70055-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr70055-cr-0002" contrib-type="author"><name name-style="western"><surname>Maas</surname><given-names initials="EJ">Ellie J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1035-7279</contrib-id><xref rid="pcmr70055-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr70055-cr-0003" contrib-type="author"><name name-style="western"><surname>DeBortoli</surname><given-names initials="E">E.</given-names></name><xref rid="pcmr70055-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pcmr70055-cr-0004" contrib-type="author"><name name-style="western"><surname>Primiero</surname><given-names initials="CA">Clare A.</given-names></name><xref rid="pcmr70055-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcmr70055-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr70055-cr-0005" contrib-type="author"><name name-style="western"><surname>Soyer</surname><given-names initials="HP">H. Peter</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4770-561X</contrib-id><xref rid="pcmr70055-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="pcmr70055-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pcmr70055-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>McInerney&#8208;Leo</surname><given-names initials="A">Aideen</given-names></name><xref rid="pcmr70055-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>a.mcinerney@uq.edu.au</email></address></contrib></contrib-group><aff id="pcmr70055-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Frazer Institute</named-content>
<institution>The University of Queensland, Dermatology Research Centre</institution>
<city>Brisbane</city>
<named-content content-type="country-part">Queensland</named-content>
<country country="AU">Australia</country>
</aff><aff id="pcmr70055-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Princess Alexandra Hospital</institution>
<city>Brisbane</city>
<named-content content-type="country-part">Queensland</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Aideen McInerney&#8208;Leo (<email>a.mcinerney@uq.edu.au</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>38</volume><issue seq="170">5</issue><issue-id pub-id-type="pmc-issue-id">497679</issue-id><issue-id pub-id-type="doi">10.1111/pcmr.v38.5</issue-id><elocation-id>e70055</elocation-id><history><date date-type="rev-recd"><day>27</day><month>8</month><year>2025</year></date><date date-type="received"><day>31</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Pigment Cell &amp; Melanoma Research</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PCMR-38-0.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PCMR-38-0.pdf"/><abstract><title>ABSTRACT</title><p>This study reports co&#8208;segregation of a pathogenic <italic toggle="no">CDKN2A</italic> variant with both melanoma and breast cancer in a four&#8208;generation pedigree. Eighteen individuals were test positive (<italic toggle="no">n</italic>&#8201;=&#8201;10), obligate (<italic toggle="no">n</italic>&#8201;=&#8201;5) or assumed carriers (<italic toggle="no">n</italic>&#8201;=&#8201;3) of the <italic toggle="no">CDKN2A</italic> variant. Eleven of these had multiple melanomas, with initial diagnoses from teens to fifties. Six of thirteen female carriers had breast cancer (<italic toggle="no">n</italic>&#8201;=&#8201;5 test positive, <italic toggle="no">n</italic>&#8201;=&#8201;1 assumed carrier), with diagnoses ranging from thirties to sixties. Additional cancer diagnoses included pancreatic, and head and neck cancers. This study illustrates a possible genotype&#8211;phenotype association between a pathogenic <italic toggle="no">CDKN2A</italic> variant and the co&#8208;occurrence of melanoma and breast cancer in a hereditary context.</p></abstract><abstract abstract-type="graphical"><p>
<italic toggle="no">CDKN2A</italic> is a well&#8208;known melanoma susceptibility gene, which also confers an increased risk for pancreatic cancer. This three&#8208;generation pedigree shows a <italic toggle="no">CDKN2A</italic> variant co&#8208;segregating with both melanoma (orange) and breast cancer (blue). This report, combined with previous case studies, illustrates an increased risk for breast cancer for specific <italic toggle="no">CDKN2A</italic> variants.<boxed-text position="anchor" content-type="graphic" id="pcmr70055-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PCMR-38-0-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pcmr70055-kwd-0001">breast cancer</kwd><kwd id="pcmr70055-kwd-0002"><italic toggle="no">CDKN2A</italic></kwd><kwd id="pcmr70055-kwd-0003">familial</kwd><kwd id="pcmr70055-kwd-0004">germline</kwd><kwd id="pcmr70055-kwd-0005">melanoma</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="5"/><word-count count="3300"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:26.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="pcmr70055-cit-1001"><string-name name-style="western"><surname>Berkman</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Maas</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>DeBortoli</surname></string-name>, <string-name name-style="western"><given-names>C. A.</given-names><surname>Primiero</surname></string-name>, <string-name name-style="western"><given-names>H. P.</given-names><surname>Soyer</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>McInerney&#8208;Leo</surname></string-name>. <year>2025</year>. &#8220;<article-title>Germline <styled-content style="fixed-case" toggle="no">
<italic toggle="no">CDKN2A</italic>
</styled-content> Variant Cascade Testing Across Four Generations Reveals Familial Melanoma&#8211;Breast Cancer Genotype&#8211;Phenotype Correlation</article-title>.&#8221; <source>Pigment Cell &amp; Melanoma Research</source><volume>38</volume>, no. <issue>5</issue>: <elocation-id>e70055</elocation-id>. <pub-id pub-id-type="doi">10.1111/pcmr.70055</pub-id>.<pub-id pub-id-type="pmid">41006694</pub-id></mixed-citation>
</p><fn-group id="pcmr70055-ntgp-0001"><fn fn-type="funding" id="pcmr70055-note-0001"><p>
<bold>Funding:</bold> H.P.S. holds an NHMRC MRFF Next Generation Clinical Researchers Program Practitioner Fellowship (APP1137127). A.M.&#8208;L. is currently supported by a University of Queensland Faculty of Medicine Fellowship. This work was also made possible by a Metro South Health Research Support Scheme Program Grant (RSS_2021_028). Funding for whole&#8208;exome sequencing was provided by Queensland Genomics, Queensland Government, Round 1 Demonstration Project grant. This research was carried out at the Translational Research Institute (TRI), Woolloongabba, Queensland, Australia.</p></fn><fn fn-type="equal" id="pcmr70055-note-0002"><p>Jennifer Berkman and Ellie J. Maas equally contributed to this work.</p></fn></fn-group></notes></front><body id="pcmr70055-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="pcmr70055-blkfxd-1001" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="pcmr70055-list-0001"><list-item id="pcmr70055-li-0001"><p>To the best of our knowledge, this is the first report of both primary melanoma and breast cancer co&#8208;segregating with a <italic toggle="yes">CDKN2A</italic> variant in a large pedigree.</p></list-item><list-item id="pcmr70055-li-0002"><p>Validating this genotype&#8211;phenotype correlation in additional pedigrees could significantly enhance clinicians' ability to assess risk and tailor personalized screening strategies to other high&#8208;risk individuals.</p></list-item></list>
</p></boxed-text>
</p><sec sec-type="opening-section" id="pcmr70055-sec-0003"><p>Breast cancer and primary melanoma are the second and third most common cancers in Australia, respectively, accounting for 28% and 11% of all cancer diagnoses each year (Australian Institute of Health and Welfare&#160;<xref rid="pcmr70055-bib-0003" ref-type="bibr">2024</xref>). The most frequently implicated predisposition genes are <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> for breast cancer (Kuchenbaecker et&#160;al.&#160;<xref rid="pcmr70055-bib-0015" ref-type="bibr">2017</xref>) and <italic toggle="yes">CDKN2A</italic> for familial melanoma (Cust et&#160;al.&#160;<xref rid="pcmr70055-bib-0008" ref-type="bibr">2011</xref>). A variant in a predisposition gene significantly increases the cumulative risk of developing these cancers by 80&#8201;years of age, with an estimated lifetime risk of 69%&#8211;72% for <italic toggle="yes">BRCA1/BRCA2</italic> mutation&#8208;positive breast cancer (Kuchenbaecker et&#160;al.&#160;<xref rid="pcmr70055-bib-0015" ref-type="bibr">2017</xref>), and 52% for <italic toggle="yes">CDKN2A</italic> mutation&#8208;positive melanoma (Cust et&#160;al.&#160;<xref rid="pcmr70055-bib-0008" ref-type="bibr">2011</xref>).</p><p>Approximately, 1%&#8211;3% of melanoma cases are classified as familial, and 20%&#8211;40% of those cases are attributed to a variant in a high&#8208;risk melanoma gene (<italic toggle="yes">CDKN2A, POT1, BAP1, POLE, CDK4, TERT, TERF2IP, ACD</italic>) (Maas et&#160;al.&#160;<xref rid="pcmr70055-bib-0018" ref-type="bibr">2022</xref>; Potrony et&#160;al.&#160;<xref rid="pcmr70055-bib-0021" ref-type="bibr">2015</xref>). <italic toggle="yes">CDKN2A</italic> accounts for 67%&#8211;84% of variant positive cases (Maas et&#160;al.&#160;<xref rid="pcmr70055-bib-0020" ref-type="bibr">2025</xref>). Individuals carrying a pathogenic variant in a high&#8208;penetrance melanoma gene are more likely to have a family history of melanoma, an earlier age of melanoma onset, and/or be diagnosed with multiple primary melanoma (Zocchi et&#160;al.&#160;<xref rid="pcmr70055-bib-0027" ref-type="bibr">2021</xref>). While <italic toggle="yes">CDKN2A</italic> is primarily associated with an increased risk for familial melanoma, hereditary cancer predisposition syndrome studies have demonstrated that <italic toggle="yes">CDKN2A</italic> also increases the relative risk for pancreatic cancer (12.3&#8208;fold) (Kimura et&#160;al.&#160;<xref rid="pcmr70055-bib-0014" ref-type="bibr">2021</xref>) and respiratory cancers (4.9&#8211;15.6) (Kimura et&#160;al.&#160;<xref rid="pcmr70055-bib-0014" ref-type="bibr">2021</xref>; Helgadottir et&#160;al.&#160;<xref rid="pcmr70055-bib-0013" ref-type="bibr">2014</xref>; Borg et&#160;al.&#160;<xref rid="pcmr70055-bib-0004" ref-type="bibr">2000</xref>). <italic toggle="yes">CDKN2A</italic> produces two tumour suppressor proteins, the canonical p16INK4a and the alternate p14ARF. The majority of <italic toggle="yes">CDKN2A</italic> variants reported in association with melanoma are loss&#8208;of&#8208;function (LOF) missense variants located in p16INK4a (Goldstein&#160;<xref rid="pcmr70055-bib-0012" ref-type="bibr">2004</xref>).</p><p>Variants in moderate&#8208;risk melanoma genes (<italic toggle="yes">MITF, MC1R, GOLM1, ATM, EBF3, NEK11</italic>) have also been found to alter melanoma risk (Potrony et&#160;al.&#160;<xref rid="pcmr70055-bib-0021" ref-type="bibr">2015</xref>; Dalmasso and Ghiorzo&#160;<xref rid="pcmr70055-bib-0009" ref-type="bibr">2020</xref>; Maas et&#160;al.&#160;<xref rid="pcmr70055-bib-0019" ref-type="bibr">2023</xref>; Wallingford et&#160;al.&#160;<xref rid="pcmr70055-bib-0026" ref-type="bibr">2024</xref>). Specifically, <italic toggle="yes">MC1R</italic> has nine common red hair colour (RHC) variants classified as &#8216;r&#8217; (V60L, V92M and R163Q) and &#8216;R&#8217; (D84E, R142H, R151C, R160W, D294H and I155T), which increase melanoma risk by approximately 1.5&#8208; and 2.0&#8208;fold, respectively (Cust et&#160;al.&#160;<xref rid="pcmr70055-bib-0007" ref-type="bibr">2012</xref>). Furthermore, RHC variants have been proven to modify the penetrance of <italic toggle="yes">CDKN2A</italic> variants by increasing the risk of early&#8208;onset melanoma (&lt;&#8201;40&#8208;years of age) and multiple primary melanoma (Box et&#160;al.&#160;<xref rid="pcmr70055-bib-0005" ref-type="bibr">2001</xref>).</p><p>This study reports segregation of a <italic toggle="yes">CDKN2A</italic> variant with both hereditary melanoma and breast cancer in an extensive pedigree. Five of the six individuals in the family with a personal history of breast cancer underwent panel testing of hereditary breast cancer genes (including <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">TP53</italic> and <italic toggle="yes">PTEN</italic>) and no pathogenic, likely pathogenic, or variants of uncertain significance were identified. Prior to study commencement, the sixth individual died of metastatic cancer (diagnosis 30&#8211;40&#8201;years) having been diagnosed with both breast cancer and melanoma.</p><p>Whole exome sequencing and subsequent clinical panel testing were performed on a proband (II:1; Female) who had &gt;&#8201;20 melanoma diagnoses (initial diagnosis in twenties) and breast cancer (diagnosis 50&#8211;60&#8201;years). Genetic testing identified a rare (minor allele frequency&#8201;=&#8201;0.00001) <italic toggle="yes">CDKN2A</italic> LOF missense variant affecting both p16INK4a and p14ARF transcripts (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000077.5">NM_000077.5</ext-link>:c.159G&gt;C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="NP_000068.1">NP_000068.1</ext-link>:p.Met53Ile) and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_058195.4">NM_058195.4</ext-link>:c.202G&gt;C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="NP_478102.2">NP_478102.2</ext-link>:p.Asp68His) respectively) which has been previously reported as pathogenic in melanoma (Lang et&#160;al.&#160;<xref rid="pcmr70055-bib-0017" ref-type="bibr">2007</xref>) and pancreatic cancer (Kimura et&#160;al.&#160;<xref rid="pcmr70055-bib-0014" ref-type="bibr">2021</xref>), and is classified as pathogenic in ClinVar as per American College of Medical Genetics (ACMG) criteria (Landrum et&#160;al.&#160;<xref rid="pcmr70055-bib-0016" ref-type="bibr">2014</xref>). Functional studies of this variant have shown that the base change significantly reduces the <italic toggle="yes">CDKN2A</italic> (p16INK4a) cell&#8208;cycle inhibitory function through downstream inhibition of Rb, increasing the risk for uncontrolled cell proliferation in not only melanocytes but also mammary epithelial cells and pancreatic epithelial cells (Kimura et&#160;al.&#160;<xref rid="pcmr70055-bib-0014" ref-type="bibr">2021</xref>; Danishevich et&#160;al.&#160;<xref rid="pcmr70055-bib-0010" ref-type="bibr">2023</xref>). This variant also alters the p14ARF transcript, potentially inhibiting p53, a cell cycle regulator (Sargen et&#160;al.&#160;<xref rid="pcmr70055-bib-0024" ref-type="bibr">2022</xref>). Pathogenic variants impacting the function of both p16INK4a and p14ARF are associated with a wider spectrum of cancer risks than variants that impact either transcript alone (Sargen et&#160;al.&#160;<xref rid="pcmr70055-bib-0024" ref-type="bibr">2022</xref>). However, it has been suggested that p14ARF has a minimal tumour suppressive role in breast cancer (Aftab et&#160;al.&#160;<xref rid="pcmr70055-bib-0002" ref-type="bibr">2019</xref>). Cascade testing was offered to all living relatives of the proband, and ten consented to provide a saliva sample for genetic testing through the Familial Melanoma Clinic at the Princess Alexandra Hospital.</p><p>The four&#8208;generation pedigree (Figure&#160;<xref rid="pcmr70055-fig-0001" ref-type="fig">1</xref>) as reported by the proband (II:1), and confirmed by individuals undergoing testing, included an extensive cancer history. Fifteen individuals had a reported personal history of melanoma alone. Six individuals had early onset (initially diagnosed from 15 to 30&#8201;years); the youngest diagnosed in her teens (IV:3). Five of these underwent genetic testing, and all were positive for the <italic toggle="yes">CDKN2A</italic> variant. An additional relative with multiple melanomas diagnosed in his forties was an obligate carrier (II:9). One relative (II:14) who tested negative was diagnosed with late&#8208;onset single primary melanoma (diagnosed 60&#8211;70&#8201;years), which is consistent with sporadic melanoma presentation in Queensland Australia, thus representing a phenocopy. A further five individuals had a history of both melanoma and breast cancer (two of whom were diagnosed with early&#8208;onset melanoma). Four of these were living and accepted testing with positive results. One relative (II:13) with breast cancer only also tested positive. A remaining unaffected relative (II:3) who consented to genetic testing received a negative result. Family history revealed a deceased relative (I:1) had a history of early onset melanoma (diagnosed 30&#8211;40&#8201;years) and pancreatic cancer (diagnosed 60&#8211;70&#8201;years), another (II:8) died of metastatic colorectal cancer (30&#8211;40&#8201;years), and an additional relative (III:8) was diagnosed with leukemia in his teens.</p><fig position="float" fig-type="FIGURE" id="pcmr70055-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Family pedigree. Four generation pedigree showing cancer diagnoses and <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">MC1R</italic> status. Arrow denotes proband; *identifies those who have had genetic testing in our clinic; OC, obligate carrier; AC, assumed carrier. Some details have been changed to ensure confidentiality.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PCMR-38-0-g002.jpg"/></fig><p>Where possible, <italic toggle="yes">MC1R</italic> variants were evaluated in positive individuals, given the association with melanoma risk. Of the 10 individuals who tested positive for the <italic toggle="yes">CDKN2A</italic> variant, eight had a personal history of melanoma and seven of these had <italic toggle="yes">MC1R</italic> RHC genotyping. All except one (III:10) of these individuals carried &#8805;&#8201;1 <italic toggle="yes">MC1R</italic> RHC variant. Four of those individuals also had a history of primary breast cancer. Of note, the remaining individual who had a history of breast cancer, but not melanoma, had a <italic toggle="yes">CDKN2A</italic> variant in the absence of an <italic toggle="yes">MC1R</italic> RHC variant (III:2). Individual characteristics and <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">MC1R</italic> RHC variant carrier status are listed in Table&#160;<xref rid="pcmr70055-tbl-0001" ref-type="table">1</xref> and denoted on the pedigree (Figure&#160;<xref rid="pcmr70055-fig-0001" ref-type="fig">1</xref>).</p><table-wrap position="float" id="pcmr70055-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Summary of characteristics and genetic status for <italic toggle="no">CDKN2A</italic> positive individuals and assumed/obligate carriers.<xref rid="pcmr70055-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Individual on pedigree</th><th align="center" valign="bottom" rowspan="1" colspan="1">Age</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sex</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">CDKN2A</italic> M53I</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">MC1R</italic> variants</th><th align="center" valign="bottom" rowspan="1" colspan="1">#Melanoma(s)/Dx age</th><th align="center" valign="bottom" rowspan="1" colspan="1">Other cancer/Dx age</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">I:1</td><td align="center" valign="top" rowspan="1" colspan="1">d. 70s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Obligate carrier</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Single primary Dx 30s</td><td align="center" valign="top" rowspan="1" colspan="1">Pancreas/60s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I:2</td><td align="center" valign="top" rowspan="1" colspan="1">d. 70s</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Obligate carrier</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Single primary Dx 30s</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I:3</td><td align="center" valign="top" rowspan="1" colspan="1">d. 80s</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Obligate carrier</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 40s</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I:4</td><td align="center" valign="top" rowspan="1" colspan="1">d. 90s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Obligate carrier</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 50s</td><td align="center" valign="top" rowspan="1" colspan="1">Cervix/40s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:1</td><td align="center" valign="top" rowspan="1" colspan="1">60s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/R</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 20s</td><td align="center" valign="top" rowspan="1" colspan="1">Breast/50s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:2</td><td align="center" valign="top" rowspan="1" colspan="1">60s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/R</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 20s</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:4</td><td align="center" valign="top" rowspan="1" colspan="1">60s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/r</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 50s</td><td align="center" valign="top" rowspan="1" colspan="1">Breast/60s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:5</td><td align="center" valign="top" rowspan="1" colspan="1">60s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/r</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 20s</td><td align="center" valign="top" rowspan="1" colspan="1">Breast/40s Head &amp; Neck<xref rid="pcmr70055-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>/50s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:9</td><td align="center" valign="top" rowspan="1" colspan="1">70s</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Obligate carrier</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">&#8212;</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 40s</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:10</td><td align="center" valign="top" rowspan="1" colspan="1">d.30s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Assumed carrier</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Single primary Dx 30s</td><td align="center" valign="top" rowspan="1" colspan="1">Breast/30s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:12</td><td align="center" valign="top" rowspan="1" colspan="1">70s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/R</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 40s</td><td align="center" valign="top" rowspan="1" colspan="1">Breast/40s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II:13</td><td align="center" valign="top" rowspan="1" colspan="1">70s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/wt</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Breast/50s</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III:1</td><td align="center" valign="top" rowspan="1" colspan="1">40s</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Assumed carrier</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Single primary Dx 20s</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III:2</td><td align="center" valign="top" rowspan="1" colspan="1">40s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/R</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III:3</td><td align="center" valign="top" rowspan="1" colspan="1">40s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/R</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 20s</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III:5</td><td align="center" valign="top" rowspan="1" colspan="1">40s</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Assumed carrier</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Single primary Dx 30s</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III:10</td><td align="center" valign="top" rowspan="1" colspan="1">50s</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">wt/wt</td><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx 50s</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IV:3</td><td align="center" valign="top" rowspan="1" colspan="1">Teens</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Multiple primaries First Dx teens</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot id="pcmr70055-ntgp-0002"><fn id="pcmr70055-note-0003"><p>Abbreviations: Dx, diagnosis; r, MC1R variant moderately associated with red hair color; R, MC1R variant strongly associated with red hair color; wt, wildtype.</p></fn><fn id="pcmr70055-note-0004"><label>
<sup>a</sup>
</label><p>As reported by family members who completed genetic testing.</p></fn><fn id="pcmr70055-note-0005"><label>
<sup>b</sup>
</label><p>Non&#8208;smoker.</p></fn></table-wrap-foot></table-wrap><p>The identified <italic toggle="yes">CDKN2A</italic> p.Met53Ile has been reported in familial melanoma cases globally in families of White&#8208;European ancestry, including families from Australia (Walker et&#160;al.&#160;<xref rid="pcmr70055-bib-0025" ref-type="bibr">1995</xref>), North America (FitzGerald et&#160;al.&#160;<xref rid="pcmr70055-bib-0011" ref-type="bibr">1996</xref>) and the United Kingdom (Lang et&#160;al.&#160;<xref rid="pcmr70055-bib-0017" ref-type="bibr">2007</xref>). More specifically, a study investigated 18 families of Scottish ancestry which revealed data supporting p.Met53Ile being a founder mutation that arose now around 90 generations ago (Lang et&#160;al.&#160;<xref rid="pcmr70055-bib-0017" ref-type="bibr">2007</xref>). Breast cancer was reported in three of those families; however, no further information on the number of affected individuals or age&#8208;of&#8208;onset was provided (Lang et&#160;al.&#160;<xref rid="pcmr70055-bib-0017" ref-type="bibr">2007</xref>). An increased prevalence of breast cancer has been reported in some <italic toggle="yes">CDKN2A</italic> positive families, including nine families with a duplication of three bases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000077.5?report=graph&amp;search=NM_000077.5%3Ac.335_337dup" ext-link-type="uri">NM_000077.5:c.335_337dup</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="NP_000068.1">NP_000068.1</ext-link>:p.Arg112dup)) in which breast cancer incidence was collectively increased (Borg et&#160;al.&#160;<xref rid="pcmr70055-bib-0004" ref-type="bibr">2000</xref>; Potrony et&#160;al.&#160;<xref rid="pcmr70055-bib-0022" ref-type="bibr">2014</xref>). However, a statistically significant risk of breast cancer in <italic toggle="yes">CDKN2A</italic> carriers has not been not been consistently reported (Kimura et&#160;al.&#160;<xref rid="pcmr70055-bib-0014" ref-type="bibr">2021</xref>; Helgadottir et&#160;al.&#160;<xref rid="pcmr70055-bib-0013" ref-type="bibr">2014</xref>; Borg et&#160;al.&#160;<xref rid="pcmr70055-bib-0004" ref-type="bibr">2000</xref>). As pancreatic cancer is elevated in <italic toggle="yes">CDKN2A</italic> carriers, all individuals over 50&#8201;years of age were referred to a pancreatic cancer screening study (Broseghini et&#160;al.&#160;<xref rid="pcmr70055-bib-0006" ref-type="bibr">2025</xref>).</p><p>A limitation of our study is that not all family members consented to cascade testing and thus segregation could not be confirmed in five living individuals with a personal history of melanoma. Furthermore, while no individuals had pathogenic variants in the four breast cancer predisposition genes tested, not all genes implicated in familial breast cancer were tested. It is possible that the increased incidence of breast cancer in this family is due to a variant in a different gene. Melanoma diagnoses were confirmed through pathology reports, where available. All breast cancers were self&#8208;reported, but this has been associated with a high degree of accuracy (97%) in the literature (Abraham et&#160;al.&#160;<xref rid="pcmr70055-bib-0001" ref-type="bibr">2009</xref>). Additionally, sun damage was not assessed, though prior research has shown that UV exposure does not predict the risk of developing melanoma in <italic toggle="yes">CDKN2A</italic> positive individuals (Cust et&#160;al.&#160;<xref rid="pcmr70055-bib-0008" ref-type="bibr">2011</xref>).</p><p>This study reports <italic toggle="yes">CDKN2A</italic> genetic testing results and affection status of twelve relatives in a four&#8208;generation pedigree. <italic toggle="yes">CDKN2A</italic> carriers had a history of early&#8208;onset and/or multiple melanoma (youngest in their teens), and the majority carried an <italic toggle="yes">MC1R</italic> RHC variant. Six of thirteen women (46%) in this pedigree assumed or confirmed to have a <italic toggle="yes">CDKN2A</italic> p.Met53Ile variant had a personal history of breast cancer. Diagnosis ages ranged from the thirties to sixties. Four of the seven women without breast cancer were under 50&#8201;years of age, after which age breast cancer risk in the general population is most frequently diagnosed (Rojas and Stuckey&#160;<xref rid="pcmr70055-bib-0023" ref-type="bibr">2016</xref>). To our knowledge, this is the first extended pedigree with both primary melanoma and breast cancer co&#8208;segregating with a pathogenic <italic toggle="yes">CDKN2A</italic> variant. Confirming this genotype&#8211;phenotype correlation in other pedigrees could assist clinicians in assessing risk and personalizing screening.</p></sec><sec id="pcmr70055-sec-0009"><title>Author Contributions</title><p>Conceptualization: A.M.&#8208;L., J.B., and H.P.S. Data curation and analysis: J.B., E.J.M., and A.M.&#8208;L. Writing: J.B., E.J.M., and A.M.&#8208;L. Review and editing: J.B., E.J.M., E.D., C.A.P., H.P.S., and A.M.&#8208;L.</p></sec><sec id="pcmr70055-sec-0008"><title>Ethics Statement</title><p>This study was approved by the Human Research Ethics Committees of the Princess Alexandra Hospital (HREC/2019/QMS/55944) and the University of Queensland (UQ2020000771) and conducted in accordance with the Declaration of Helsinki.</p></sec><sec sec-type="conclusions" id="pcmr70055-sec-0006"><title>Consent</title><p>Consent for the publication of de&#8208;identified patient data was obtained by the authors prior to article submission stating that the participant gave consent with the understanding that this information may be publicly available.</p></sec><sec sec-type="COI-statement" id="pcmr70055-sec-0007"><title>Conflicts of Interest</title><p>H.P.S. is a shareholder of MoleMap NZ Limited and e&#8208;derm consult GmbH and undertakes regular teledermatological reporting for both companies. H.P.S. is a Medical Consultant for Canfield Scientific Inc., Blaze Bioscience Inc., MoleMap Australia Pty Limited, and a Medical Advisor for First Derm. Other authors declare no conflicts of interest.</p></sec></body><back><ack id="pcmr70055-sec-1024"><title>Acknowledgements</title><p>Open access publishing facilitated by The University of Queensland, as part of the Wiley &#8208; The University of Queensland agreement via the Council of Australian University Librarians.</p></ack><sec sec-type="data-availability" id="pcmr70055-sec-0005"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="pcmr70055-bibl-0001"><title>References</title><ref id="pcmr70055-bib-0001"><mixed-citation publication-type="journal" id="pcmr70055-cit-0001"><string-name name-style="western"><surname>Abraham</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>B. M.</given-names><surname>Geller</surname></string-name>, <string-name name-style="western"><given-names>B. C.</given-names><surname>Yankaskas</surname></string-name>, et&#160;al. <year>2009</year>. &#8220;<article-title>Accuracy of Self&#8208;Reported Breast Cancer Among Women Undergoing Mammography</article-title>.&#8221; <source>Breast Cancer Research and Treatment</source><volume>118</volume>: <fpage>583</fpage>&#8211;<lpage>592</lpage>.<pub-id pub-id-type="pmid">19301119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-009-0375-4</pub-id><pub-id pub-id-type="pmcid">PMC2784159</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0002"><mixed-citation publication-type="journal" id="pcmr70055-cit-0002"><string-name name-style="western"><surname>Aftab</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Shahzad</surname></string-name>, <string-name name-style="western"><given-names>H. M. J.</given-names><surname>Hussain</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Irum</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Tabassum</surname></string-name>. <year>2019</year>. &#8220;<article-title>CDKN2A/P16INK4A Variants Association With Breast Cancer and Their In&#8208;Silico Analysis</article-title>.&#8221; <source>Breast Cancer</source><volume>26</volume>: <fpage>11</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">30039340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12282-018-0894-0</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0003"><mixed-citation publication-type="miscellaneous" id="pcmr70055-cit-0003"><collab collab-type="authors">Australian Institute of Health and Welfare</collab>
. <year>2024</year>. <article-title>&#8220;Cancer Data in Australia.&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/overview-of-cancer-in-australia-2023" ext-link-type="uri">https://www.aihw.gov.au/reports/cancer/cancer&#8208;data&#8208;in&#8208;australia/contents/overview&#8208;of&#8208;cancer&#8208;in&#8208;australia&#8208;2023</ext-link>.</mixed-citation></ref><ref id="pcmr70055-bib-0004"><mixed-citation publication-type="journal" id="pcmr70055-cit-0004"><string-name name-style="western"><surname>Borg</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Sandberg</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nilsson</surname></string-name>, et&#160;al. <year>2000</year>. &#8220;<article-title>High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation&#8208;Positive Melanoma Families</article-title>.&#8221; <source>Journal of the National Cancer Institute</source><volume>92</volume>, no. <issue>15</issue>: <fpage>1260</fpage>&#8211;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">10922411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/92.15.1260</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0005"><mixed-citation publication-type="journal" id="pcmr70055-cit-0005"><string-name name-style="western"><surname>Box</surname>, <given-names>N. F.</given-names></string-name>, <string-name name-style="western"><given-names>D. L.</given-names><surname>Duffy</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Chen</surname></string-name>, et&#160;al. <year>2001</year>. &#8220;<article-title>MC1R Genotype Modifies Risk of Melanoma in Families Segregating CDKN2A Mutations</article-title>.&#8221; <source>American Journal of Human Genetics</source><volume>69</volume>, no. <issue>4</issue>: <fpage>765</fpage>&#8211;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1086/323412</pub-id>.<pub-id pub-id-type="pmid">11500805</pub-id><pub-id pub-id-type="pmcid">PMC1226062</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0006"><mixed-citation publication-type="journal" id="pcmr70055-cit-0006"><string-name name-style="western"><surname>Broseghini</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Venturi</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Veronesi</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer</article-title>.&#8221; <source>Pigment Cell &amp; Melanoma Research</source><volume>38</volume>, no. <issue>1</issue>: <elocation-id>e13210</elocation-id>.<pub-id pub-id-type="pmid">39609109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.13210</pub-id><pub-id pub-id-type="pmcid">PMC11681848</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0007"><mixed-citation publication-type="journal" id="pcmr70055-cit-0007"><string-name name-style="western"><surname>Cust</surname>, <given-names>A. E.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Goumas</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Holland</surname></string-name>, et&#160;al. <year>2012</year>. &#8220;<article-title>MC1R Genotypes and Risk of Melanoma Before Age 40&#8201;Years: A Population&#8208;Based Case&#8208;Control&#8208;Family Study</article-title>.&#8221; <source>International Journal of Cancer</source><volume>131</volume>, no. <issue>3</issue>: <fpage>E269</fpage>&#8211;<lpage>E281</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.27357</pub-id>.<pub-id pub-id-type="pmid">22095472</pub-id><pub-id pub-id-type="pmcid">PMC4330189</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0008"><mixed-citation publication-type="journal" id="pcmr70055-cit-0008"><string-name name-style="western"><surname>Cust</surname>, <given-names>A. E.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Harland</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Makalic</surname></string-name>, et&#160;al. <year>2011</year>. &#8220;<article-title>Melanoma Risk for CDKN2A Mutation Carriers Who Are Relatives of Population&#8208;Based Case Carriers in Australia and the UK</article-title>.&#8221; <source>Journal of Medical Genetics</source><volume>48</volume>, no. <issue>4</issue>: <fpage>266</fpage>&#8211;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2010.086538</pub-id>.<pub-id pub-id-type="pmid">21325014</pub-id><pub-id pub-id-type="pmcid">PMC7432952</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0009"><mixed-citation publication-type="journal" id="pcmr70055-cit-0009"><string-name name-style="western"><surname>Dalmasso</surname>, <given-names>B.</given-names></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Ghiorzo</surname></string-name>. <year>2020</year>. &#8220;<article-title>Evolution of Approaches to Identify Melanoma Missing Heritability</article-title>.&#8221; <source>Expert Review of Molecular Diagnostics</source><volume>20</volume>, no. <issue>5</issue>: <fpage>523</fpage>&#8211;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1080/14737159.2020.1738221</pub-id>.<pub-id pub-id-type="pmid">32124637</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0010"><mixed-citation publication-type="journal" id="pcmr70055-cit-0010"><string-name name-style="western"><surname>Danishevich</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Bilyalov</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Nikolaev</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes</article-title>.&#8221; <source>Biomedicine</source><volume>11</volume>, no. <issue>12</issue>: <fpage>3343</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11123343</pub-id><pub-id pub-id-type="pmcid">PMC10741544</pub-id><pub-id pub-id-type="pmid">38137564</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0011"><mixed-citation publication-type="journal" id="pcmr70055-cit-0011"><string-name name-style="western"><surname>FitzGerald</surname>, <given-names>M. G.</given-names></string-name>, <string-name name-style="western"><given-names>D. P.</given-names><surname>Harkin</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Silva&#8208;Arrieta</surname></string-name>, et&#160;al. <year>1996</year>. &#8220;<article-title>Prevalence of Germ&#8208;Line Mutations in p16, p19ARF, and CDK4 in Familial Melanoma: Analysis of a Clinic&#8208;Based Population</article-title>.&#8221; <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>93</volume>, no. <issue>16</issue>: <fpage>8541</fpage>&#8211;<lpage>8545</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.93.16.8541</pub-id>.<pub-id pub-id-type="pmid">8710906</pub-id><pub-id pub-id-type="pmcid">PMC38708</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0012"><mixed-citation publication-type="journal" id="pcmr70055-cit-0012"><string-name name-style="western"><surname>Goldstein</surname>, <given-names>A. M.</given-names></string-name><year>2004</year>. &#8220;<article-title>Familial Melanoma, Pancreatic Cancer and Germline CDKN2A Mutations</article-title>.&#8221; <source>Human Mutation</source><volume>23</volume>, no. <issue>6</issue>: <fpage>630</fpage>. <pub-id pub-id-type="doi">10.1002/humu.9247</pub-id>.<pub-id pub-id-type="pmid">15146471</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0013"><mixed-citation publication-type="journal" id="pcmr70055-cit-0013"><string-name name-style="western"><surname>Helgadottir</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>H&#246;iom</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>J&#246;nsson</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>High Risk of Tobacco&#8208;Related Cancers in CDKN2A Mutation&#8208;Positive Melanoma Families</article-title>.&#8221; <source>Journal of Medical Genetics</source><volume>51</volume>, no. <issue>8</issue>: <fpage>545</fpage>&#8211;<lpage>552</lpage>.<pub-id pub-id-type="pmid">24935963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmedgenet-2014-102320</pub-id><pub-id pub-id-type="pmcid">PMC4112445</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0014"><mixed-citation publication-type="journal" id="pcmr70055-cit-0014"><string-name name-style="western"><surname>Kimura</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>A. P.</given-names><surname>Klein</surname></string-name>, <string-name name-style="western"><given-names>R. H.</given-names><surname>Hruban</surname></string-name>, and <string-name name-style="western"><given-names>N. J.</given-names><surname>Roberts</surname></string-name>. <year>2021</year>. &#8220;<article-title>The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer</article-title>.&#8221; <source>Pancreas</source><volume>50</volume>, no. <issue>8</issue>: <fpage>1123</fpage>&#8211;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">34714275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPA.0000000000001888</pub-id><pub-id pub-id-type="pmcid">PMC8562885</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0015"><mixed-citation publication-type="journal" id="pcmr70055-cit-0015"><string-name name-style="western"><surname>Kuchenbaecker</surname>, <given-names>K. B.</given-names></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Hopper</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Barnes</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers</article-title>.&#8221; <source>JAMA</source><volume>317</volume>, no. <issue>23</issue>: <fpage>2402</fpage>&#8211;<lpage>2416</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.7112</pub-id>.<pub-id pub-id-type="pmid">28632866</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0016"><mixed-citation publication-type="journal" id="pcmr70055-cit-0016"><string-name name-style="western"><surname>Landrum</surname>, <given-names>M. J.</given-names></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>G. R.</given-names><surname>Riley</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>ClinVar: Public Archive of Relationships Among Sequence Variation and Human Phenotype</article-title>.&#8221; <source>Nucleic Acids Research</source><volume>42</volume>, no. <issue>D1</issue>: <fpage>D980</fpage>&#8211;<lpage>D985</lpage>.<pub-id pub-id-type="pmid">24234437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt1113</pub-id><pub-id pub-id-type="pmcid">PMC3965032</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0017"><mixed-citation publication-type="journal" id="pcmr70055-cit-0017"><string-name name-style="western"><surname>Lang</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Hayward</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Goldgar</surname></string-name>, et&#160;al. <year>2007</year>. &#8220;<article-title>The M53I Mutation in CDKN2A Is a Founder Mutation That Predominates in Melanoma Patients With Scottish Ancestry</article-title>.&#8221; <source>Genes, Chromosomes &amp; Cancer</source><volume>46</volume>, no. <issue>3</issue>: <fpage>277</fpage>&#8211;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.20410</pub-id>.<pub-id pub-id-type="pmid">17171691</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0018"><mixed-citation publication-type="journal" id="pcmr70055-cit-0018"><string-name name-style="western"><surname>Maas</surname>, <given-names>E. J.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Betz&#8208;Stablein</surname></string-name>, <string-name name-style="western"><given-names>L. G.</given-names><surname>Aoude</surname></string-name>, <string-name name-style="western"><given-names>H. P.</given-names><surname>Soyer</surname></string-name>, and <string-name name-style="western"><given-names>A. M.</given-names><surname>McInerney&#8208;Leo</surname></string-name>. <year>2022</year>. &#8220;<article-title>Unusual Suspects in Hereditary Melanoma: POT1, POLE, BAP1</article-title>.&#8221; <source>Trends in Genetics</source><volume>38</volume>, no. <issue>12</issue>: <fpage>1204</fpage>&#8211;<lpage>1207</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2022.06.007</pub-id>.<pub-id pub-id-type="pmid">35811174</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0019"><mixed-citation publication-type="journal" id="pcmr70055-cit-0019"><string-name name-style="western"><surname>Maas</surname>, <given-names>E. J.</given-names></string-name>, <string-name name-style="western"><given-names>C. K.</given-names><surname>Wallingford</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>De Bortoli</surname></string-name>, et&#160;al. <year>2023</year>. &#8220;<article-title>GOLM1: Expanding Our Understanding of Melanoma Susceptibility</article-title>.&#8221; <source>Journal of Medical Genetics</source><volume>60</volume>: <fpage>835</fpage>&#8211;<lpage>837</lpage>. <pub-id pub-id-type="doi">10.1136/jmg-2023-109348</pub-id>.<pub-id pub-id-type="pmid">37487699</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0020"><mixed-citation publication-type="journal" id="pcmr70055-cit-0020"><string-name name-style="western"><surname>Maas</surname>, <given-names>E. J.</given-names></string-name>, <string-name name-style="western"><given-names>C. K.</given-names><surname>Wallingford</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>De Bortoli</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>Prevalence of High&#8208;Risk Melanoma Variants in Early Onset and/or Multiple Primary Melanoma in an Australia Cohort</article-title>.&#8221; <source>Journal of the European Academy of Dermatology and Venereology</source>. <pub-id pub-id-type="doi">10.1111/jdv.20673</pub-id>.<pub-id pub-id-type="pmid">40192034</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0021"><mixed-citation publication-type="journal" id="pcmr70055-cit-0021"><string-name name-style="western"><surname>Potrony</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Badenas</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Aguilera</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>Update in Genetic Susceptibility in Melanoma</article-title>.&#8221; <source>Annals of Translational Medicine</source><volume>3</volume>, no. <issue>15</issue>: <fpage>210</fpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2305-5839.2015.08.11</pub-id>.<pub-id pub-id-type="pmid">26488006</pub-id><pub-id pub-id-type="pmcid">PMC4583600</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0022"><mixed-citation publication-type="journal" id="pcmr70055-cit-0022"><string-name name-style="western"><surname>Potrony</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Puig&#8208;Butill&#233;</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Aguilera</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Increased Prevalence of Lung, Breast, and Pancreatic Cancers in Addition to Melanoma Risk in Families Bearing the Cyclin&#8208;Dependent Kinase Inhibitor 2A Mutation: Implications for Genetic Counseling</article-title>.&#8221; <source>Journal of the American Academy of Dermatology</source><volume>71</volume>, no. <issue>5</issue>: <fpage>888</fpage>&#8211;<lpage>895</lpage>.<pub-id pub-id-type="pmid">25064638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2014.06.036</pub-id><pub-id pub-id-type="pmcid">PMC4250348</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0023"><mixed-citation publication-type="journal" id="pcmr70055-cit-0023"><string-name name-style="western"><surname>Rojas</surname>, <given-names>K.</given-names></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Stuckey</surname></string-name>. <year>2016</year>. &#8220;<article-title>Breast Cancer Epidemiology and Risk Factors</article-title>.&#8221; <source>Clinical Obstetrics and Gynecology</source><volume>59</volume>, no. <issue>4</issue>: <fpage>651</fpage>&#8211;<lpage>672</lpage>.<pub-id pub-id-type="pmid">27681694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GRF.0000000000000239</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0024"><mixed-citation publication-type="journal" id="pcmr70055-cit-0024"><string-name name-style="western"><surname>Sargen</surname>, <given-names>M. R.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Helgadottir</surname></string-name>, <string-name name-style="western"><given-names>X. R.</given-names><surname>Yang</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers</article-title>.&#8221; <source>JNCI Cancer Spectrum</source><volume>6</volume>, no. <issue>6</issue>: <elocation-id>pkac074</elocation-id>.<pub-id pub-id-type="pmid">36269225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncics/pkac074</pub-id><pub-id pub-id-type="pmcid">PMC9667970</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0025"><mixed-citation publication-type="journal" id="pcmr70055-cit-0025"><string-name name-style="western"><surname>Walker</surname>, <given-names>G. J.</given-names></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Hussussian</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Flores</surname></string-name>, et&#160;al. <year>1995</year>. &#8220;<article-title>Mutations of the CDKN2/p16INK4 Gene in Australian Melanoma Kindreds</article-title>.&#8221; <source>Human Molecular Genetics</source><volume>4</volume>, no. <issue>10</issue>: <fpage>1845</fpage>&#8211;<lpage>1852</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/4.10.1845</pub-id>.<pub-id pub-id-type="pmid">8595405</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0026"><mixed-citation publication-type="journal" id="pcmr70055-cit-0026"><string-name name-style="western"><surname>Wallingford</surname>, <given-names>C. K.</given-names></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Maas</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Howard</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>MITF E318K: A Rare Homozygous Case With Multiple Primary Melanoma</article-title>.&#8221; <source>Pigment Cell &amp; Melanoma Research</source><volume>37</volume>, no. <issue>1</issue>: <fpage>68</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">37635363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.13122</pub-id></mixed-citation></ref><ref id="pcmr70055-bib-0027"><mixed-citation publication-type="journal" id="pcmr70055-cit-0027"><string-name name-style="western"><surname>Zocchi</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Lontano</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Merli</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management</article-title>.&#8221; <source>Journal of Clinical Medicine</source><volume>10</volume>, no. <issue>16</issue>: <elocation-id>3760</elocation-id>. <pub-id pub-id-type="doi">10.3390/jcm10163760</pub-id>.<pub-id pub-id-type="pmid">34442055</pub-id><pub-id pub-id-type="pmcid">PMC8397216</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>